Morgan Stanley analyst Robert Davies lowered the firm’s price target on Medacta Group to CHF 107 from CHF 109 and keeps an Overweight rating on the shares.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly